

## SUSPECT ADVERSE REACTION REPORT

## I. REACTION INFORMATION

1. PATIENT INITIALS (first, last) <b>PRIVACY</b>	1a. COUNTRY <b>COSTA RICA</b>	2. DATE OF BIRTH Day Month Year <b>PRIVACY</b>	2a. AGE <b>Unk</b>	3. SEX <b>Male</b>	3a. WEIGHT <b>Unk</b>	4-6 REACTION ONSET Day Month Year <b>MAY 2025</b>	8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION <input type="checkbox"/> PATIENT DIED <input type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALISATION <input type="checkbox"/> INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY <input type="checkbox"/> LIFE THREATENING <input type="checkbox"/> CONGENITAL ANOMALY <input type="checkbox"/> OTHER
7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data) Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas) <b>Many eating disorders [Eating disorder]</b>  Case Description: ***This is an auto generated narrative***  Study ID: 828652-My Healthy Journey  Study description: Trial title: This is a 40 weeks digital patient support program with focus on exercise, motivation, nutrition & maintaining strategies (only for patients under Liraglutide 3.0 mg).  (Continued on Additional Information Page)							

## II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name) <b>#1 ) Saxenda (liraglutide 6 mg/mL) Solution for injection, 6 mg/mL</b> (Continued on Additional Information Page)	20. DID REACTION ABATE AFTER STOPPING DRUG? <input checked="" type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> NA
15. DAILY DOSE(S) <b>#1 ) UNK</b>	16. ROUTE(S) OF ADMINISTRATION <b>#1 ) Subcutaneous</b>
17. INDICATION(S) FOR USE <b>#1 ) Product used for unknown indication (P)</b> (Continued on Additional Information Page)	21. DID REACTION REAPPEAR AFTER REINTRODUCTION? <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> NA
18. THERAPY DATES(from/to) <b>#1 ) MAY-2024 / Unknown</b>	19. THERAPY DURATION <b>#1 ) Unknown</b>

## III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) From/To Dates Type of History / Notes Description <b>Unknown</b>

## IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER <b>Novo Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888</b>	26. REMARKS <b>Medically Confirmed: No</b>
24b. MFR CONTROL NO. <b>1470618</b>	25b. NAME AND ADDRESS OF REPORTER <b>NAME AND ADDRESS WITHHELD.</b>
24c. DATE RECEIVED BY MANUFACTURER <b>26-JUN-2025</b>	24d. REPORT SOURCE <input checked="" type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input type="checkbox"/> HEALTH PROFESSIONAL <input type="checkbox"/> OTHER:
DATE OF THIS REPORT <b>11-JUL-2025</b>	25a. REPORT TYPE <input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP:

---

**ADDITIONAL INFORMATION****7+13. DESCRIBE REACTION(S) continued**

This non-serious Solicited Report from COSTA RICA was reported by a Consumer as "Many eating disorders(Eating disorder)" beginning on MAY-2025 and concerned a Male patient who was treated with Saxenda (liraglutide 6 mg/mL) from MAY-2024 to FEB-2025 for "Product used for unknown indication",

## Dosage Regimens:

Saxenda: ??-MAY-2024 to Not Reported, Not Reported to ??-FEB-2025;

Medical history was not provided.

## Batch Numbers:

Saxenda: UNK, UNK;

Action taken to Saxenda was reported as Product discontinued due to AE.

The outcome for the event "Many eating disorders(Eating disorder)" was Recovering/resolving.

## Reporter's causality (Saxenda) -

Many eating disorders(Eating disorder) : Unknown

## Company's causality (Saxenda) -

Many eating disorders(Eating disorder) : Unlikely

Reporter Comment: Treatment received: Unspecified-non codeable

**14-19. SUSPECT DRUG(S) continued**

14. SUSPECT DRUG(S) (include generic name)	15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN	17. INDICATION(S) FOR USE	18. THERAPY DATES (from/to); 19. THERAPY DURATION
#1 ) Saxenda (liraglutide 6 mg/mL) Solution for injection, 6 mg/mL; Regimen #1	UNK; Subcutaneous	Product used for unknown indication (Product used for unknown indication)	MAY-2024 / Unknown; Unknown
#1 ) Saxenda (liraglutide 6 mg/mL) Solution for injection, 6 mg/mL; Regimen #2	1.8 mg, qd; Subcutaneous	Product used for unknown indication (Product used for unknown indication)	Unknown / FEB-2025; Unknown